Icatibant Injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of Hereditary angioedema (HAE) in adults 18 years of age and older. It is not known if Icatibant Injection is safe or effective for children under 18 years of age.
Icatibant Injection, manufactured by Fresenius Kabi, is less expensive, easy to use, and made with the same quality ingredients used in the brand-name product.
Fresenius Kabi also offers an industry-standard patient support program, KabiCare. Patient support resources are available for eligible patients.
Fresenius Kabi is a leading provider of generic medications with a 100-year history of delivering innovative therapies that are safe, efficient, and affordable.